Cortex Pharmaceuticals, Inc. (OTC: CORX) has multiple drug development programs targeted toward the treatment of brain-related breathing disorders, such as obstructive or central sleep apnea and drug-induced respiratory depression. One key program involves the development of positive allosteric modulators of the AMPA-type glutamate receptor (PAM-A compounds), which can prevent and/or rescue respiratory depression, a potentially lethal side effect of opiate analgesics or anesthetic agents such as propofol, without affecting the beneficial analgesic or anesthetic activity of such agents. For more information, visit the company’s website at www.cortexpharm.com.